

DICOM Change Proposal

STATUS	Assigned
Date of Last Update	5 June 2025
Person Assigned	steven.nichols@gehealthcare.com
Submitter Name	keran.elazari@gehealthcare.com
Submission Date	4 March 2025

Change Number	CP-2512
Log Summary:	Add radiopharmaceutical codes
Name of Standard	PS3.16

Rationale for Change:

Include additional Radiopharmaceuticals and Isotopes utilized in PET and NM.

References:

- Kumar P, Emami S, Kresolek Z, Yang J, McEwan AJ, Wiebe LI. Synthesis and hypoxia selective radiosensitization potential of beta-2-FAZA and beta-3-FAZL: fluorinated azomycin beta-nucleosides. *Med Chem.* 2009 Mar;5(2):118-29. doi: 10.2174/157340609787582945. PMID: 19275710.
- Ehrin E, Stone-Elander S, Nilsson JL, Bergström M, Blomqvist G, Brismar T, Eriksson L, Greitz T, Jansson PE, Litton JE, Malmberg P, af Ugglas M, Widén L. C-11-labeled glucose and its utilization in positron-emission tomography. *J Nucl Med.* 1983 Apr;24(4):326-31. PMID: 6601185.
- Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, O'Sullivan F, Krohn KA. 2-[C-11]thymidine imaging of malignant brain tumors. *Cancer Res.* 1999 Feb 1;59(3):615-21. PMID: 9973209.
- Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. *Synapse.* 2003 Feb;47(2):123-33. doi: 10.1002/syn.10155. PMID: 12454950.
- Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, Brouwers AH, Hiltermann TJN, van der Wekken AJ, Hijmering-Kappelle LBM, Timens W, Elias SG, Hospers GAP, Groen HJM, Uytendil W, van der Hiel B, Haanen JB, de Groot DJA, Jalving M, de Vries EGE. 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. *Ann Oncol.* 2022 Jan;33(1):80-88. doi: 10.1016/j.annonc.2021.10.213. Epub 2021 Nov 1. PMID: 34736925.
- Huclier-Markai S, Alliot C, Kerdjoudj R, Chouin N, Haddad F, Davodeau F. Promising radionuclides for targeted alpha therapy: a review. *Nucl Med Biol.* 2016 Sep;43(5):523–541. doi: 10.1016/j.nucmedbio.2016.03.002. PMID: 27014673.
- Müller C, Reber J, Haller S, Dorner H, Köster U, Johnston K, et al. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostic applications. *EJNMMI Radiopharm Chem.* 2017 Dec;2(1):5. doi: 10.1186/s41181-017-0021-4. PMID: 28649642.
- Kazakov A, Singh A, Müller C, Leung K, Domnanich KA, Kaeppli SA, et al. First-in-humans SPECT/CT imaging of metastatic prostate cancer with terbium-161-labeled PSMA-617. *J Nucl Med.* 2023 Aug;64(8):1322–1325. doi: 10.2967/jnumed.122.265496. PMID: 36862853.
- Kratochwil C, Kunert M, Rathke H, Happel C, Köhn A, Linxweiler J, et al. First-in-human application of 211At-labeled PSMA ligand: functional alpha imaging and therapy of mCRPC. *Eur J Nucl Med Mol Imaging.* 2024;51:1596–1602. doi: 10.1007/s00259-024-07017-w. PMID: 38496283.
- Tagawa ST, Milowsky MI, Sartor AO, Vlachostergios PJ, Singer EA, Ko CJ, et al. Phase I dose-escalation study of 225Ac-J591 for men with mCRPC: updated results. *J Nucl Med.* 2022 May;63(Suppl 2):3251.
- Zwarthoed C, Desmonts C, Peyronneau MA, Gonon G, Kriza C, Le Duc G, et al. Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy. *EJNMMI Res.* 2024 Apr 30;14(1):48. doi: 10.1186/s13550-024-01056-z. PMID: 38698292.
- Bernhardt P, Forssell-Aronsson E, Bäck T, Jacobsson L, Johanson K. Rat renal dosimetry and biokinetics of 213Bi- and 225Ac-labeled MX35 F(ab')₂ antibodies for ovarian cancer treatment. *J Nucl Med.* 2016 Mar;57(3):486–492. doi: 10.2967/jnumed.115.161646. PMID: 26576896.

Change Wording:

Amend PS3.16 Chapter B DCMR Context Groups Table CID 18 Radiopharmaceutical Isotope as follows

Table CID 18. Radiopharmaceutical Isotope

Coding Scheme Designator	Code Value	Code Meaning	SNOMED-RT ID	UMLS Concept Unique ID
...				
<u>SCT</u>	<u>66956003</u>	<u>Iodine-122</u>		<u>C0303022</u>
<u>MSH</u>	<u>C000615359</u>	<u>Scandium-47</u>		<u>C4546991</u>
<u>SCT</u>	<u>68153002</u>	<u>Xenon-123</u>		<u>C0303674</u>
<u>MSH</u>	<u>C000615034</u>	<u>Terbium-149</u>		<u>C4546779</u>
<u>MSH</u>	<u>C000615038</u>	<u>Terbium-161</u>		<u>C4546782</u>
<u>MSH</u>	<u>C000615146</u>	<u>Astatine-211</u>		<u>C4546839</u>
<u>SCT</u>	<u>87401005</u>	<u>Lead-212</u>		<u>C0303247</u>
<u>MSH</u>	<u>C000615137</u>	<u>Bismuth-213</u>		<u>C4546830</u>
<u>SCT</u>	<u>32059002</u>	<u>Actinium-225</u>		<u>C0303084</u>

Amend PS3.16 Chapter B DCMR Context Groups Table CID 25 Radiopharmaceutical as follows

10

Table CID 25. Radiopharmaceutical

Coding Scheme Designator	Code Value	Code Meaning	SNOMED-RT ID	UMLS Concept Unique ID	Trade name (Informative)
...					
<u>SCT</u>	<u>1263794005</u>	<u>Lutetium Lu-177 vipivotide tetraxetan</u>		<u>C4308025</u>	<u>PLUVICTO</u>

Amend PS3.16 Chapter B DCMR Context Groups Table CID 4021 PET Radiopharmaceutical as follows

15

Table CID 4021. PET Radiopharmaceutical

Coding Scheme Designator	Code Value	Code Meaning	SNOMED-RT ID	UMLS Concept Unique ID	Other Names
...					
<u>SCT</u>	<u>764937002</u>	<u>Fluorothymidine (18-F)</u>		<u>C1432709</u>	
<u>SCT</u>	<u>771875003</u>	<u>N-Methylspiperone</u>		<u>C4750094</u>	
<u>DCM</u>	<u>newCODE1</u>	<u>Carbon-11 Glucose</u>			
<u>NCIt</u>	<u>C148167</u>	<u>Zirconium Z- 89 Pembrolizumab</u>		<u>C4724867</u>	
<u>MSH</u>	<u>C412822</u>	<u>(11C)DASB</u>		<u>C1570551</u>	
<u>NCIt</u>	<u>C90936</u>	<u>2-(C-11)Thymidine</u>		<u>C2983946</u>	
<u>NCIt</u>	<u>C62520</u>	<u>Fluoroazomycin arabinoside F-18</u>		<u>C1566975</u>	<u>18F-FAZA</u>

Amend PS3.16 Table D-1. DICOM Controlled Terminology Definitions as follows

Table D-1. DICOM Controlled Terminology Definitions (Coding Scheme Designator "DCM" Coding Scheme Version "01")

Code Value	Code Meaning	Definition	Notes
...			
<u>newCODE1</u>	<u>Carbon-11 Glucose</u>	<u>Carbon-11 Glucose PET Radiotracer.</u>	